This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through March 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
ImmunityBio vs. Moderna: Which Biotech Has More Upside Potential?
by Sundeep Ganoria
IBRX and MRNA hinge on single-drug success, but pipeline depth, growth plans and risks set them apart in the race for biotech upside.
MRKNegative Net Change MRNAPositive Net Change IBRXNegative Net Change
biotechs medical medical-devices messenger-rna pharmaceuticals vaccines
Can Gilead's Recent Acquisitions Strengthen Its Long-Term Growth Outlook?
by Zacks Equity Research
Gilead doubles down on acquisitions, adding immunology and CAR-T assets to diversify beyond HIV and strengthen its oncology pipeline.
NVSPositive Net Change BMYNegative Net Change GILDNegative Net Change
biotechnology biotechs medical pharmaceuticals
Denali Wins FDA Nod for Hunter Syndrome Drug, Stock Up
by Zacks Equity Research
DNLI surges after FDA approves Avlayah, its first commercial drug and a breakthrough Hunter syndrome therapy targeting the brain.
SNYPositive Net Change BIIBNegative Net Change DNLINegative Net Change TAKNegative Net Change
biotechnology biotechs medical pharmaceuticals
SRPT Stock Surges on Promising Early Results From siRNA Programs
by Zacks Equity Research
Sarepta Therapeutics shares surge 35% as early data from two siRNA therapies show strong target knockdown, safety and muscle delivery potential.
SRPTNegative Net Change CPRXNegative Net Change INOPositive Net Change ADMANegative Net Change
biotechs
Merck to Boost Oncology Pipeline With $6.7B Terns Buyout, Stock Up
by Zacks Equity Research
MRK's $6.7B Terns buyout is set to add a promising leukemia drug candidate, boosting its oncology pipeline as it prepares for Keytruda's patent cliff.
MRKNegative Net Change AMRNNegative Net Change TERNPositive Net Change
biotechs pharmaceuticals
ALT Stock and the 2026 MASH Race: Dual Agonists vs. New Mechanisms
by Kinjel Shah
Altimmune heads into a pivotal 2026 MASH race, betting its dual agonist pemvidutide can stand out in a crowded field as key catalysts and risks converge.
NVOPositive Net Change LLYNegative Net Change ALTNegative Net Change MDGLNegative Net Change
biotechs
BEAM Eyes Global Expansion of AATD Study After Strong Early Data
by Zacks Equity Research
Beam Therapeutics reports promising phase I/II data for BEAM-302 in AATD, showing strong efficacy, tolerability and potential as a one-time curative treatment.
BEAMNegative Net Change CPRXNegative Net Change INOPositive Net Change ADMANegative Net Change
biotechs
Altimmune Stock: Neutral Outlook With Big 2026 Catalysts
by Kinjel Shah
Altimmune heads into 2026 with high-stakes catalysts as pemvidutide drives its pipeline, but funding needs and dilution risk loom alongside key clinical readouts.
NVOPositive Net Change LLYNegative Net Change ALTNegative Net Change
biotechs
ALT Pemvidutide Explained: What Makes It Different in MASH
by Kinjel Shah
Altimmune's pemvidutide targets MASH with dual glucagon/GLP-1 biology, showing mid-stage promise as it advances toward a high-stakes phase III study.
NVOPositive Net Change LLYNegative Net Change ALTNegative Net Change MDGLNegative Net Change
biotechs
Cancer Stocks to Buy as Innovation Reshapes Global Oncology Market
by Kinjel Shah
Oncology is evolving fast as immunotherapy, AI and targeted drugs expand treatment options, boost outcomes, and fuel long-term healthcare growth.
AZNPositive Net Change NVSPositive Net Change JNJNegative Net Change PFENegative Net Change MRKNegative Net Change VSTMNegative Net Change XLONo Net Change
biotechs cancer